Skip to Content

New Drug Approvals Archive - May 2012

May 2012

Elelyso (taliglucerase alfa) - formerly Uplyso

Date of Approval: May 1, 2012
Company: Protalix BioTherapeutics, Inc.
Treatment for: Gaucher Disease

Elelyso (taliglucerase alfa) is a plant-cell expressed recombinant form of glucocerebrosidase for the treatment of Gaucher disease.

Dymista (azelastine and fluticasone) Nasal Spray

Date of Approval: May 1, 2012
Company: Meda Pharmaceuticals, Inc.
Treatment for: Allergic Rhinitis

Dymista (azelastine and fluticasone) nasal spray is an H1-receptor antagonist and corticosteroid combination indicated for the relief of symptoms of seasonal allergic rhinitis.

Fabior (tazarotene) Foam

Date of Approval: May 11, 2012
Company: Stiefel Laboratories, Inc.
Treatment for: Acne

Fabior (tazarotene) Foam is a retinoid indicated for the topical treatment of acne vulgaris.

Pertzye (pancrelipase) Delayed Release Capsules

Date of Approval: May 17, 2012
Company: Digestive Care, Inc.
Treatment for: Pancreatic Exocrine Dysfunction

Pertzye (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.